Healthy subjects, Parkinson'
Conditions
Interventions
Intravenous injection of 18F-fluoro-dopa and 11C-raclopride
PET imaging
Sponsors
Institute of Biomedical Research and Innovation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy over 35 years old Subjects who do not have clinically abnormal findings in the head MRI Subjects who informed consent was obtained Sbjects who do not have healthy problem to participate in clinical research Parkinson's disease/Parkinson's syndrome over 35 years old Sbjects who has been diagnosed with Parkinson's disease or Parkinson's syndrome clinically Subjects who have normal finding or do not have organic lesions to doubt Parkinson's syndrome associated with the central nervous system degenerative disease in MRI imaging Subjects who informed consent was obtained Sbjects who do not have healthy problem to participate in clinical research
Exclusion criteria
Exclusion criteria: Subjects who consciousness is not clear Subjects with cerebrovascular disorder Subjects with cardiac dysfunction Subjects with QT prolongation and ventricular arrhythmias on the electrocardiogram Subjects with liver and kidney failure Subjects with gastric ulcer and duodenal ulcer Subjects with diabetes Subjects with serious lung disease, bronchial asthma and endocrine disease Subjects with angle-closure glaucoma and chronic open-angle glaucoma Subjects who are psychiatric symptoms such as suicidal tendencies Subjects who are taking non-selective monoamine oxidase inhibitors Subjects who suffer from the symptomatic parkinsonism by clear organic cause Subjects who have the history of drug allergy Subjects who it is difficult to skip Parkinson treatment medicine from the day before Subjects with rhabdomyolysis Subjects with malignant syndrome Subjects with pheochromocytoma Subjects with prolactin-secreting pituitary tumor Subjects who are dehydration and malnutrition state Subjects Who exhibit a strong response to drink Subjects who are drug dependence, alcohol dependence Subjects who have participated in clinical research within the past 3 months Subjects who reserchers judged as inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Integrated ratio of striatum and cerebellum cortex or the occipital lobe | — |
Secondary
| Measure | Time frame |
|---|---|
| Standard uptake value(SUV) of the striatum | — |
Countries
Japan
Contacts
Public ContactAkihito Ohnishi
Institute of Biomedical Research and Innovation Division of Molecular Imaging
Outcome results
None listed